Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are supported by the provided label excerpts (HBV reactivation warning and HBV testing; general drug interaction concept). However, several parts are either not directly supported by the provided text (common side effects, headache claim) or overgeneralized beyond the supplied sections (e.g., 'severe liver problems' framing and 'managed through screening and monitoring rather than dose changes').
Category Scores
Accurate Statements
Clinicians check for hepatitis B infection before starting Epclusa.
Label excerpt 2.1 Testing Prior to the Initiation of Therapy: requires testing all patients for current or prior HBV infection (HBsAg and anti-HBc) before initiating HCV treatment with EPCLUSA.
Hepatitis B can reactivate in people who have had hepatitis B before or have coinfection when taking Epclusa.
Label excerpt 5 WARNING: describes HBV reactivation reported in HCV/HBV coinfected patients undergoing or having completed HCV direct acting antivirals who were not receiving HBV antiviral therapy; also directs testing for current or prior HBV infection.
Hepatitis B reactivation in people taking Epclusa can lead to severe liver problems.
Label excerpt 5 WARNING: states some cases have resulted in fulminant hepatitis, hepatic failure, and death; and recommends appropriate patient management as clinically indicated.
Severe liver problems related to hepatitis B reactivation may require monitoring and treatment.
Label excerpt 5 WARNING: recommends monitoring HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during treatment and post-treatment follow-up, and initiating appropriate patient management for HBV infection as clinically indicated.
Epclusa can interact with other medicines.
Label excerpt 7 Drug Interactions (7.1): describes drug transporter/CYP effects and that drugs that are inducers may decrease sofosbuvir/velpatasvir concentrations; also notes EPCLUSA may be coadministered with inhibitors.
Drug interactions with Epclusa can affect safety and tolerability.
Label excerpt 7.1: explains inducers may decrease plasma concentrations leading to reduced therapeutic effect; while the excerpt does not explicitly say 'safety and tolerability,' it does address clinical impact of interactions (reduced therapeutic effect) and references warnings. No direct 'safety and tolerability' wording provided in the supplied text.
Unsupported Statements
Epclusa (sofosbuvir/velpatasvir) can cause tiredness (fatigue).
The provided label excerpts include HBV testing/warning and drug interactions; they do not list fatigue as an adverse reaction or discuss common side effects.
Epclusa (sofosbuvir/velpatasvir) can cause headache.
The provided label excerpts do not support headache as an adverse reaction.
The most commonly reported side effects of Epclusa are fatigue and headache.
No 'most commonly reported' side effects content is present in the supplied label excerpts.
The main serious risk associated with Epclusa involves use with certain hepatitis C antiviral medicines.
The provided WARNING text mentions HBV reactivation in patients undergoing or had completed HCV direct acting antivirals without HBV antiviral therapy, but does not state this is the 'main serious risk associated with Epclusa.'
The main serious risk associated with Epclusa involves use with medications that affect hepatitis B.
The provided WARNING text discusses risk in coinfected patients and the role of HBV antiviral therapy; it does not describe the 'main serious risk' as specifically involving 'use with medications that affect hepatitis B.'
Hepatitis B reactivation in people who have had hepatitis B before or have coinfection when taking Epclusa.
The warning text specifically emphasizes HBV reactivation in HCV/HBV coinfected patients not receiving HBV antiviral therapy; it does not directly state reactivation occurs for all 'had hepatitis B before' cases absent the HCV/HBV coinfection and therapy context in the provided excerpt.
Severe liver problems related to hepatitis B reactivation may require monitoring and treatment.
This is partially supported; however, the statement is broad. The excerpt supports monitoring and initiating appropriate patient management, but does not specifically tie 'may require monitoring and treatment' to 'severe liver problems' as a named consequence beyond fulminant hepatitis/hepatic failure/death.
Epclusa can interact with other medicines.
Not unsupported overall, but the provided statement 'can interact' is supported; the earlier 'safety and tolerability' portion is not clearly supported as phrased.
Drug interactions with Epclusa can affect safety and tolerability.
The supplied interaction excerpt does not explicitly connect to 'safety and tolerability.'
Hepatitis B reactivation risk with Epclusa is managed through screening and monitoring rather than dose changes.
The warning excerpt recommends testing and monitoring and initiating appropriate management as clinically indicated; it does not explicitly state that management is 'rather than dose changes.'
Contradictions
Low
AI Statement
The main serious risk associated with Epclusa involves use with medications that affect hepatitis B.
Label Reference
5 WARNING text is about HBV reactivation in HCV/HBV coinfected patients not receiving HBV antiviral therapy; it does not define the risk as 'use with medications that affect hepatitis B.'
Important Omissions
No mention in the response of the specific boxed warning directive to 'Test all patients for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc' prior to initiating EPCLUSA.
Importance:
Moderate
No mention of the listed serious adverse reaction 'Serious Symptomatic Bradycardia When Coadministered with Amiodarone' (as an example from supplied section 6).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
HBV testing/monitoring and HBV reactivation risk statements are generally aligned with the provided warning. However, unsupported statements about fatigue/headache common side effects and overgeneralized management framing could mislead readers if treated as label-accurate.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims (fatigue/headache and 'most commonly reported' side effects; and the 'managed through screening and monitoring rather than dose changes' framing) are not supported by the supplied label excerpts.
Suggested Improvement
Remove or qualify claims not supported by the provided sections; restrict HBV management wording to what the warning excerpt states (test with HBsAg/anti-HBc, monitor for flare/reactivation, initiate appropriate management as clinically indicated).